145 related articles for article (PubMed ID: 21557144)
1. Long-term follow-up of pediatric patients treated with mitoxantrone for multiple sclerosis.
Kornek B; Bernert G; Rostasy K; Mlczoch E; Feucht M; Prayer D; Vass K; Seidl R
Neuropediatrics; 2011 Feb; 42(1):7-12. PubMed ID: 21557144
[TBL] [Abstract][Full Text] [Related]
2. Management of worsening multiple sclerosis with mitoxantrone: a review.
Fox EJ
Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of mitoxantrone, as an initial therapy, in multiple sclerosis: experience in an Indian tertiary care setting.
Singhal BS; Geeta S; Hundalani SG; Menon S
Neurol India; 2009; 57(4):418-23. PubMed ID: 19770542
[TBL] [Abstract][Full Text] [Related]
4. Long-term safety profile of mitoxantrone in a French cohort of 802 multiple sclerosis patients: a 5-year prospective study.
Le Page E; Leray E; Edan G;
Mult Scler; 2011 Jul; 17(7):867-75. PubMed ID: 21325016
[TBL] [Abstract][Full Text] [Related]
5. [Immunosuppressive therapy of multiple sclerosis with mitoxantrone].
Mauch E; Kornhuber HH
Fortschr Neurol Psychiatr; 1993 Dec; 61(12):410-7. PubMed ID: 8112704
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the myocardial performance index for early detection of mitoxantrone-induced cardiotoxicity in patients with multiple sclerosis.
Pattoneri P; Pelà G; Montanari E; Pesci I; Moruzzi P; Borghetti A
Eur J Echocardiogr; 2007 Mar; 8(2):144-50. PubMed ID: 16603413
[TBL] [Abstract][Full Text] [Related]
7. [Use of mitoxantrone in early multiple sclerosis with malignant disease course. Observational study in 30 patients with clinical and MRI outcomes after one year].
Ory S; Debouverie M; Le Page E; Pelletier J; Malikova I; Gout O; Roullet E; Vermersch P; Edan G
Rev Neurol (Paris); 2008 Dec; 164(12):1028-34. PubMed ID: 18808781
[TBL] [Abstract][Full Text] [Related]
8. Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: an open-label comparative study of efficacy and safety.
Zipoli V; Portaccio E; Hakiki B; Siracusa G; Sorbi S; Amato MP
J Neurol Sci; 2008 Mar; 266(1-2):25-30. PubMed ID: 17870094
[TBL] [Abstract][Full Text] [Related]
9. [Mitoxantrone].
Pericot I; Montalban X
Neurologia; 2003; 18(6):318-23. PubMed ID: 12838451
[TBL] [Abstract][Full Text] [Related]
10. Mitoxantrone reduced disability in Iranian patients with multiple sclerosis.
Hamzehloo A; Etemadifar M
Arch Iran Med; 2007 Jan; 10(1):59-64. PubMed ID: 17198456
[TBL] [Abstract][Full Text] [Related]
11. A double-blind clinical trial of mitoxantrone versus methylprednisolone in relapsing, secondary progressive multiple sclerosis.
van de Wyngaert FA; Beguin C; D'Hooghe MB; Dooms G; Lissoir F; Carton H; Sindic CJ
Acta Neurol Belg; 2001 Dec; 101(4):210-6. PubMed ID: 11851027
[TBL] [Abstract][Full Text] [Related]
12. Mitoxantrone for worsening multiple sclerosis: tolerability, toxicity, adherence and efficacy in the clinical setting.
Wundes A; Kraft GH; Bowen JD; Gooley TA; Nash RA
Clin Neurol Neurosurg; 2010 Dec; 112(10):876-82. PubMed ID: 20727669
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of mitoxantrone in pediatric patients with aggressive multiple sclerosis.
Etemadifar M; Afzali P; Abtahi SH; Ramagopalan SV; Nourian SM; Murray RT; Fereidan-Esfahani M
Eur J Paediatr Neurol; 2014 Mar; 18(2):119-25. PubMed ID: 24139067
[TBL] [Abstract][Full Text] [Related]
14. Long-term experience with induction treatment regimens in multiple sclerosis.
Le Page E; Edan G
J Neurol Sci; 2009 Feb; 277 Suppl 1():S46-9. PubMed ID: 19200867
[TBL] [Abstract][Full Text] [Related]
15. The current role of mitoxantrone in the treatment of multiple sclerosis.
Cocco E; Marrosu MG
Expert Rev Neurother; 2014 Jun; 14(6):607-16. PubMed ID: 24834466
[TBL] [Abstract][Full Text] [Related]
16. Use of low-dose mitozantrone to treat aggressive multiple sclerosis: a single-centre open-label study using patient self-assessment and clinical measures of multiple sclerosis status.
Ostberg A; Pittas F; Taylor B
Intern Med J; 2005 Jul; 35(7):382-7. PubMed ID: 15958106
[TBL] [Abstract][Full Text] [Related]
17. Treatment of Marburg variant multiple sclerosis with mitoxantrone.
Jeffery DR; Lefkowitz DS; Crittenden JP
J Neuroimaging; 2004 Jan; 14(1):58-62. PubMed ID: 14748210
[TBL] [Abstract][Full Text] [Related]
18. Mitoxantrone treatment in patients with early relapsing-remitting multiple sclerosis.
Cocco E; Marchi P; Sardu C; Russo P; Paolillo A; Mascia M; Solla M; Frau J; Lorefice L; Massole S; Floris G; Marrosu M
Mult Scler; 2007 Sep; 13(8):975-80. PubMed ID: 17468439
[TBL] [Abstract][Full Text] [Related]
19. Rationale for the use of mitoxantrone in multiple sclerosis.
Edan G; Morrissey S; Le Page E
J Neurol Sci; 2004 Aug; 223(1):35-9. PubMed ID: 15261558
[TBL] [Abstract][Full Text] [Related]
20. Tolerability and acceptance of prolonged low/delayed mitoxantrone regimens in patients with worsening multiple sclerosis.
Zecca C; Petrini L; Limoni C; Staedler C; Gobbi C
Eur Neurol; 2011; 65(1):40-5. PubMed ID: 21196739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
